Trial leader to speak at UK p

RNS Number : 3481A

ReNeuron Group plc

31 January 2011

 



 

 

PRESS RELEASE

 

ReNeuron stroke clinical trial leader to speak at UK public stem cell forum

Guildford, UK, 31 January 2011: ReNeuron Group plc (LSE: RENE.L) today announces thatthe Principal Investigator for the Company's Phase I clinical trial in stroke will be speaking at a public stem cell forum to be held in Scotland this week.

The event is one of a series of Stem Cell Roadshows organised by the UK National Stem Cell Network in collaboration with the Association of Medical Research Charities.  The events are designed for the general public to attend in order to gain further information on the research and development of stem cell treatments in the UK and overseas.  This week's event, organised in conjunction with the Scottish Stem Cell Network, will be held at the Royal College of Surgeons in Edinburgh on 1 February, and will focus on neurological diseases.  Professor Keith Muir, SINAPSE Professor of Clinical Imaging and Consultant Neurologist at the University of Glasgow, will speak about ReNeuron's ground-breaking clinical trial of its ReN001 stem cell therapy for disabled stroke patients, currently taking place at Glasgow's Southern General hospital.

Further information regarding this event and the Stem Cell Roadshows may be found at www.uknscn.org/public events/. 

Enquiries:

Michael Hunt, Chief Executive Officer - ReNeuron          [phone]

Dr John Sinden, Chief Scientific Officer - ReNeuron

Mark Court, Isabel Podda

Buchanan Communications                                               [phone]

Eleanor Cowie, Media Relations Officer                          [phone]

University of Glasgow

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in early clinical development.  ReNeuron's ReN009 stem cell therapy is being developed as a treatment for peripheral arterial disease, a serious and common side-effect of diabetes. The Company is also developing stem cell therapies for other conditions such as blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell^®products for use in academic and commercial research.  The Company's ReNcell^®CX and ReNcell^®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

 

END

 

 

NRAWGURAGUPGUBG